Clin2
NCT07559097Possibly a fitRecruiting

Methotrexate-loaded vesicles injected into spine fluid for lung cancer spread to brain membranes

Leptomeningeal Metastasis From Lung Cancer

Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.

This study tests a new way to deliver a cancer drug directly into the fluid around your brain and spinal cord to treat lung cancer that has spread to the membranes covering the brain. It may help patients whose cancer hasn't responded to standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
14 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have been diagnosed with lung cancer confirmed by a biopsy or cell sample
  • You have meningeal metastasis (cancer spread to the membrane around your brain and spinal cord) confirmed by finding cancer cells in your spinal fluid
  • Your lung cancer is advanced and has not responded to standard treatments
  • You are in reasonably good overall health (ECOG performance status of 0 to 3, meaning you can do light activities)
  • You are not currently enrolled in other treatment studies

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07744529Recruiting· Phase 1/Phase 2
Combination treatment for lung cancer spread to the lining of the brain

This trial tests a new combination of two drugs for people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord. The treatment aims to target the cancer cells and may help improve symptoms and survival.

Hangzhou, Zhejiang
NCT07751536Recruiting
Proton radiation and intrathecal chemo for lung cancer that has spread to the brain lining

This trial tests a combination of proton radiation to the brain and spine plus chemotherapy given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and has continued to grow despite taking a third-generation TKI medicine like osimertinib.

Hefei, Anhui
NCT07264569Recruiting· Phase 1/Phase 2
Testing a new drug for lung cancer that has spread to the brain or spinal fluid

This trial tests a new drug called BioTTT001 for people with non-small cell lung cancer (NSCLC) that has spread to the fluid around the brain or the lining of the brain (leptomeninges). The goal is to see if the drug is safe and can help control the cancer.

Zhengzhou, Henan
NCT06663306Recruiting· Phase 1
Intrathecal pemetrexed and bevacizumab for lung cancer brain spread

This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.

Shanghai
NCT06296745Recruiting· Phase 2
Pemetrexed in spinal fluid for lung cancer that spread to brain lining

This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.

Huizhou, Guangdong
NCT02422641Recruiting· Phase 2
High-dose methotrexate for breast cancer in the brain lining

This Phase 2 trial tests whether giving high-dose methotrexate into the bloodstream can help treat breast cancer that has spread to the thin lining covering the brain and spinal cord. It may help reduce cancer in the leptomeningeal (brain-lining) area and control symptoms.

Baltimore, Maryland

Hear when a new Leptomeningeal Metastasis From Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.